CD34+CD38-淋巴幼稚细胞作为可能的白血病干细胞（LSCs），可能负责对治疗的不良反应，并可能成为B细胞前体急性淋巴细胞白血病（BCP-ALL）复发的风险因素。本研究旨在评估BCP-ALL诊断日骨髓中CD34+CD38-淋巴幼稚细胞的预后作用。纳入115例BCP-ALL患者，中位年龄为4.5岁（范围1.5-17.9岁），女性63例（54.8%）。其中，I组（n=90）为CD34+CD38+抗原阳性患者，II组（n=20）为CD34+CD38-抗原阳性患者。在II组（CD34+CD38-）治疗第8、15、33天和治疗结束时观察到更多病情不良反应，但这些差异在统计学上并不显著。BCP-ALL复发发生率在II组中明显较高。1.在儿童BCP-ALL中，诊断时CD34+CD38-淋巴幼稚细胞的存在不影响首次缓解。2.在儿童BCP-ALL中，诊断时CD34+CD38-淋巴幼稚细胞的存在可能被视为不利的预后因素，与疾病复发有关。3.有必要进一步寻找儿童BCP-ALL的预后因素。© 2023 Stolpa, Mizia-Malarz, Zapała和Zwiernik。

CD34+CD38- lymphoblasts as likely leukemia stem cells (LSCs) may be responsible for a worse response to treatment and may be a risk factor for recurrence in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).The study objective was to assess the prognostic role of CD34+CD38- lymphoblasts in bone marrow on the day of BCP-ALL diagnosis.115 patients with BCP-ALL, the median age of 4.5 years (range 1.5-17.9 years), gender: female 63 (54.8%) with BCP-ALL were enrolled; Group I (n = 90)-patients with CD34+CD38+ antigens and Group II (n = 20)-patients with CD34+CD38- antigens on the lymphoblast surface.A worse response on Days 8, 15, and 33 of therapy and at the end of treatment in Group II (CD34+CD38-) was more often observed but these differences were not statistically significant. A significantly higher incidence of BCP-ALL recurrence was in Group II.1.In BCP-ALL in children, the presence of CD34+CD38- lymphoblasts at the diagnosis does not affect the first remission.2.In BCP-ALL in children, the presence of CD34+CD38- lymphoblasts at the diagnosis may be considered an unfavorable prognostic factor for disease recurrence.3.It is necessary to further search for prognostic factors in BCP-ALL in children.© 2023 Stolpa, Mizia-Malarz, Zapała and Zwiernik.